The Kiniksa pipeline has the potential to treat a spectrum of autoinflammatory & autoimmune diseases.
| Program & Target | Indication | Preclin | Phase 1 | Phase 2 | Phase 3 | Mkt | Rights | |||
|---|---|---|---|---|---|---|---|---|---|---|
| RilonaceptIL-1α & IL-1β | Recurrent Pericarditis | Phase 3 | Worldwide (excl. Middle East and North Africa) | |||||||
| MavrilimumabGM-CSFRα | Giant Cell Arteritis | Phase 2 | Worldwide | |||||||
| KPL-716OSMRβ | Prurigo Nodularis | Adaptive P2a/2b | Worldwide | |||||||
| Atopic Dermatitis | Phase 1b | Worldwide | ||||||||
| KPL-045CD30L | T-cell dependent, B-cell-mediated indications | Preclinical | Worldwide | |||||||
| KPL-404CD40 | T-cell dependent, B-cell-mediated indications | Preclinical | Worldwide | |||||||
Rilonacept is an approved, subcutaneously-administered, cytokine trap that inhibits the signaling of IL-1α and IL-1β, two soluble cytokines. There are multiple diseases involving these cytokines where rilonacept may provide benefit, the first of which is in a rare, inflammatory, cardiovascular disease where there are currently no approved therapies. We are currently enrolling RHAPSODY, a pivotal Phase 3 trial of rilonacept in recurrent pericarditis.
Monoclonal antibody inhibitor of GM-CSF signaling. Currently enrolling a global Phase 2 study in Giant Cell Arteritis - an inflammatory disease of blood vessels with unmet need.
Monoclonal antibody inhibitor of both IL-31 and Oncostatin M, cytokines involved in pruritus, Th2 response, fibrosis and barrier dysfunction.
Monoclonal antibody inhibitor of a T-cell co-stimulatory mechanism important in the function of activated T-memory cells.
Monoclonal antibody inhibitor of a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.